HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through advanced cardiac insights, announced that its management team will participate in several investor and industry conferences throughout March 2026. The company's presence at these events underscores its commitment to advancing portable cardiac monitoring technology and engaging with key stakeholders in the healthcare and investment communities.
CEO Robert Eno and CFO Timothy Cruickshank will participate in the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 16-17, 2026. During the conference, the executives will host a webcast presentation on March 16 and conduct meetings with both institutional and retail investors. This virtual format allows for broad accessibility while maintaining the company's investor relations outreach during a critical period of technology commercialization.
The management team will also attend the 38th Annual ROTH Conference in Dana Point, California, on March 23-24, 2026. At this event, CEO Robert Eno will join a panel discussion focused on technologies that advance healthy aging, positioning HeartBeam's innovations within the broader context of preventive healthcare and longevity solutions. This participation highlights the company's alignment with growing market interest in technologies that support aging populations and proactive health management.
Perhaps most significantly, CEO Robert Eno, Founder and President Dr. Branislav Vajdic, and Chief Commercial Officer Bryan Humbarger will attend ACC.26, the American College of Cardiology's annual scientific conference on March 28-30, 2026. At this premier cardiology event, the company plans to showcase its FDA-cleared HeartBeam System and demonstrate a working prototype of its 12-lead ECG extended wear patch to physicians and potential industry partners. This demonstration represents a crucial step in introducing the medical community to HeartBeam's portable cardiac monitoring solutions.
HeartBeam's technology represents a significant advancement in cardiac care, creating what the company describes as the first-ever cable-free device capable of collecting ECG signals in three dimensions from three non-coplanar directions and synthesizing these signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever patients are located, delivering what the company calls "actionable heart intelligence." The technology received FDA clearance for arrhythmia assessment in December 2024, with the 12-lead ECG synthesis software receiving clearance in December 2025. Detailed information about the cleared indications for use is available at https://www.heartbeam.com/indications.
The company's conference participation comes at a pivotal time as it seeks to establish its technology within the cardiac monitoring market. By demonstrating its working prototype to cardiologists at ACC.26, HeartBeam aims to build clinical acceptance for its approach to portable 12-lead ECG monitoring. The technology's potential to enable physicians to identify cardiac health trends and acute conditions outside traditional medical facilities could significantly impact how cardiac care is delivered, particularly for patients who require ongoing monitoring or live in remote areas.
HeartBeam holds over 20 issued patents related to its technology enablement, providing intellectual property protection as it commercializes its innovations. The company's news and updates are available in its newsroom at https://ibn.fm/BEAT. The March 2026 conference schedule represents a strategic effort to increase visibility among both financial and medical audiences during a period of technological advancement and market expansion in remote patient monitoring solutions.
